Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase-II Study to evaluate the accuracy of
Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for
early prediction of non-progression in patients with non-small-cell lung cancer (NSCLC)
treated with Erlotinib.